Employees: 314
Size Frontier Biotechnologies (688221.SS) is a China Health Care company (Biotechnology) with a market value of $658M, the 3039th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥11.94 on 18 Nov 2026.
Performance Over six months the shares fell 47.7%, against -14.7% for the median peer and -20.0% for the China market (cap-weighted) — lowest of 18 in its peer set.
Growth Revenue grew 153.4% over the last twelve months (peer median +18.1%); the operating margin is -19.6% (peer median -105.4%).
Valuation It trades at 11.4× enterprise value to sales against a peer median of 6.9× (7th most expensive of 16).
Price implies For today's price to make sense, revenue must grow about 40% a year for seven years (Req g). Recent delivered growth is +21%, so the hurdle is +19 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 15.2 points below its cost of capital (11.3% WACC).
Next results Next results expected around 26 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥358M | CN¥123M | CN¥129M | CN¥114M | CN¥84.7M |
| Revenue growth | — | -5% | +13% | +35% | — |
| Gross profit | CN¥293M | CN¥30.3M | CN¥27.0M | CN¥11.3M | -CN¥9.02M |
| EBITDA | n/a | -CN¥237M | -CN¥236M | -CN¥297M | -CN¥346M |
| Net income | -CN¥35.8M | -CN¥268M | -CN¥201M | -CN¥329M | -CN¥357M |
| Free cash flow | CN¥52.7M | -CN¥244M | -CN¥175M | -CN¥379M | -CN¥409M |
| Capital expenditure | CN¥11.1M | CN¥29.9M | CN¥18.6M | CN¥129M | CN¥140M |
| Total debt | CN¥375M | CN¥406M | CN¥407M | CN¥380M | CN¥279M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688221.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -15.9% | -7.0% | 6th lowest of 21 |
| 6-month return | -47.7% | -14.7% | lowest of 18 |
| Distance from 52-week high | -60.2% | -44.8% | 3rd lowest of 21 |
| Revenue growth (TTM) | +153.4% | +18.1% | 5th highest of 16 |
| Operating margin | -19.6% | -105.4% | 7th highest of 17 |
| EV / Sales | 11.4× | 6.9× | 7th most expensive of 16 |
| Growth the price implies (Req g, 7 yrs) | 40.3% | 4.2% | 2nd most demanding of 5 |
| Growth delivered (Del g) | +21.5% | +5.3% | highest of 5 |
| Hurdle (Req g minus delivered) | +18.8 pp | +1.4 pp | 2nd most demanding of 5 |
| ROIC minus cost of capital | -15.2 pp | -14.9 pp | 6th lowest of 12 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Frontier Biotechnologies 688221.SS | China | $658M | -48% | +153% | -20% | 11.4× | 40.3% | +21.5% |
| Shouyao Holdings Beijing 688197.SS | China | $653M | -26% | +4,564% | -92% | 38.1× | n/a | n/a |
| Alphamab Oncology 9966.HK | Hong Kong | $666M | -38% | -32% | -38% | 6.7× | n/a | n/a |
| Steminent Biotherapeutics 7729.TWO | Taiwan | $668M | +292% | n/a | n/a | n/a | n/a | n/a |
| Kura Oncology KURA | United States | $674M | -29% | -24% | -394% | 2.6× | n/a | n/a |
| Geron GERN | United States | $638M | -21% | +19% | -8% | 2.8× | n/a | n/a |
| Anhui Wanbang Pharmaceutical Technology 301520.SZ | China | $684M | +74% | -15% | -8% | 14.7× | 44.8% | +14.7% |
| Shenzhen Weiguang Biological Products 002880.SZ | China | $633M | -27% | 0% | 18% | 4.4× | n/a | n/a |
| Janux Therapeutics JANX | United States | $631M | -28% | +133% | -599% | n/a | n/a | n/a |
| Getein Biotech 603387.SS | China | $625M | -13% | +8% | 21% | 2.6× | -8.9% | -1.3% |
| Prime Medicine PRME | United States | $695M | +35% | +18% | -2,584% | 105.4× | n/a | n/a |
| Solid Biosciences SLDB | United States | $709M | -2% | n/a | n/a | n/a | n/a | n/a |
| Attovia Therapeutics ATTO | United States | $710M | +1,325% | n/a | -5,945% | 220.7× | n/a | n/a |
| Shaanxi Micot Pharmaceutical Technology 2335.HK | Hong Kong | $715M | n/a | n/a | n/a | n/a | n/a | n/a |
| Design Therapeutics DSGN | United States | $606M | -15% | n/a | n/a | n/a | n/a | n/a |
| Surrozen SRZN | United States | $605M | +17% | +192% | -485% | 48.5× | n/a | n/a |
| Anhui Huaheng Biotechnology 688639.SS | China | $605M | -45% | +7% | 3% | 1.9× | n/a | n/a |
| R&G PharmaStudies 301333.SZ | China | $722M | -11% | +21% | 11% | 3.4× | 17.3% | +11.8% |
| Apnimed APMD | United States | $726M | n/a | +380% | -140% | 10.8× | n/a | n/a |
| Alebund Pharmaceuticals (Jiangsu) 9637.HK | Hong Kong | $595M | n/a | +674% | -495% | 26.8× | n/a | n/a |
| Beijing SL Pharmaceutical 002038.SZ | China | $736M | -20% | -4% | -119% | 6.9× | -13.5% | -10.9% |